Saturday 17 October 2026
Export EVGN’s income statement to Excel — free account
Evogene Ltd.
EVGN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 35.0%, EPS grew 77.4% and free cash flow grew 17.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
0.39
0.01
−2.50%
Follow EVGN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(18.64%) | (63.29%) | (115.46%) | (100.03%) | |
Piotroski F-Score |
3 | 4 | 3 | 2 | |
| (8.30%) | (28.33%) | (45.04%) | (38.31%) | ||
ROIC |
(605.29%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(15.31%) | (65.27%) | (113.85%) | (109.23%) | |
Average Days of Receivables |
326.06 | 178.28 | 336.89 | 310.59 | |
Free Cash Flow per Share |
(1.81) | (1.72) | (1.15) | (0.88) | |
Free Cash Flow |
(15.80) | (13.56) | (11.19) | (10.78) | |
Capital Expenditures |
(0.42) | (0.06) | 0.09 | 0.17 | |
| Other line items | |||||
Cash ROIC |
(47.57%) | (54.32%) | (53.09%) | (71.31%) | |
Accounts Receivable Turnover |
0.75 | 1.53 | 0.74 | 1.04 | |
Accounts Payable Turnover |
3.02 | 4.39 | 5.13 | 5.84 | |
Inventory Turnover |
1.40 | 4.04 | 2.33 | 2.71 | |
Average Days of Payables |
66.67 | 56.97 | 62.43 | 51.79 | |
Days of Inventory on Hand |
307.96 | 18.72 | 23.60 | 12.22 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
315.64% | 207.47% | 399.24% | 426.25% | |
Selling, General and Administrative Expense of Revenue |
242.54% | 149.55% | 310.95% | 338.26% | |
Share Based Compensation of Revenue |
34.16% | 16.97% | 22.07% | 18.23% | |
Interest Coverage |
(7.43) | (7.26) | (2.64) | (2.85) | |
Operating CF/Net income |
5.60 | 1.59 | 0.96 | 1.21 | |
Depreciation/Fixed assets |
2.21 | 3.04 | 5.09 | 6.75 | |
Capex/Depreciation |
(0.16) | (0.02) | 0.02 | 0.05 | |
Revenue per Share |
0.26 | 0.49 | 0.19 | 0.14 | |
Operating CF per Share |
(1.76) | (1.71) | (1.16) | (0.90) | |
Capex per Share |
(0.05) | (0.01) | 0.01 | 0.01 | |
Capex to Sales |
0.19 | 0.01 | (0.05) | (0.10) |
Columns are period end dates